Flash Finance

Artemis Medicare Services LimitedARTEMISMEDCorporate

Healthcare Latest results: Mar 2026 13 quarters of data
Consolidated Standalone
₹306.35
MCap ₹4,799 Cr · P/E 46.2
Artemis Medicare Services Limited — Stock analysis & AI research Artemis Medicare Services Limited — Multibagger AI analysis Artemis Medicare Services Limited — Seasonality — best & worst months Artemis Medicare Services Limited — Technical setup — score, trend, support & resistance Artemis Medicare Services Limited — Live exchange announcements
📋 High Profit Growth Stocks📋 Stocks With Strong Quarterly Results 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹274 Cr
Sales · Mar 2026
+16.6% YoY
₹50 Cr
Operating Profit · Mar 2026
+40.7% YoY
18.3%
OPM % · Mar 2026
+21.2% YoY
₹30 Cr
Net Profit · Mar 2026
+29.3% YoY
₹1.87
EPS · Mar 2026
+26.4% YoY

📝 Artemis Medicare Services Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Artemis Medicare Services Limited reported revenue of ₹274 crore for the quarter ended March 2026 (Q4 FY26), up 16.6% from ₹235 crore in the same quarter last year, and up 2.5% sequentially over the December 2025 quarter.

Net profit rose 29.3% year-on-year to ₹30 crore, from ₹23 crore. Earnings per share (EPS) came in at ₹1.87.

Operating profit stood at ₹50 crore — an operating margin (OPM) of 18.3%, compared with 15.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Artemis Medicare Services Limited posted revenue of ₹1,060 crore, a growth of 16.1% over FY25, with a net profit of ₹104 crore (up 24.5% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,060 crore with a net profit of ₹104 crore.

Valuation snapshot

At the current price of ₹306.35, ARTEMISMED has a market capitalisation of ₹4,799 crore and a trailing P/E of about 46.2.

Shareholding pattern

As of Sep 2026, promoters held 58.39%, foreign institutional investors (FIIs) 12.46%, domestic institutional investors (DIIs) 1.91%, the government 6.16%, public shareholders 21.08% of Artemis Medicare Services Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹4,799 Cr
Current Price ?
₹306.4
P/E ?
46.19above ind
Industry P/E ?
34.70
P/B ?
5.11
P/S ?
4.53
P/FCF ?
191.96
Enterprise Value ?
₹5,059 Cr
EV/EBITDA ?
27.37
PEG ?
1.15
Earnings Yield ?
2.7%
Dividend Yield ?
0.14%
Profitability & Returns
Sales (TTM) ?
₹1,060 Cr
OPM ?
17.4%
Profit after tax (TTM) ?
₹104 Cr
EPS (TTM) ?
₹6.63
ROCE ?
15.0%
ROE ?
11.1%
ROA ?
7.3%
Growth
Sales — latest qtr ?
₹274 Cr
PAT — latest qtr ?
₹30 Cr
YoY qtr sales growth ?
16.6%
YoY qtr profit growth ?
29.3%
Sales growth (3y) ?
14%
Sales growth (5y) ?
21%
Profit growth (3y) ?
40%
Profit growth (5y) ?
76%
Financial Health
Debt ?
₹260 Cr
Debt to Equity ?
0.28
Interest Coverage ?
5.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
58.39%
Change in promoter holding ?
-8.14%
Pledged percentage ?
N/A
Market
Return 3 months ?
13.7%
Return 6 months ?
30.7%

🗓️ Quarterly results (13 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 187201217210217217235227235250270267274 +16.6% +2.5%
Operating Profit 25273332363642373641504450 +40.7% +14.2%
Other Income 21222479127878 -34.6% +6.8%
Interest 5678888887776 -20.3% -9.0%
Depreciation 89910101011111111111212 +6.7% -0.4%
Profit Before Tax 14131916192231272930403039 +34.5% +31.9%
Net Profit 10101412141723212321302330 +29.3% +33.3%
EPS 0.780.731.010.851.021.161.441.331.481.361.901.421.87 +26.4% +31.7%
OPM % 13.1% 13.5% 15.4% 15.1% 16.7% 16.4% 17.8% 16.2% 15.1% 16.4% 18.6% 16.4% 18.3% +21.2% +11.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹913 Cr ₹1,060 Cr ₹1,060 Cr +16.1%
Operating Profit ₹150 Cr ₹185 Cr ₹185 Cr +23.4%
OPM % 16.41% 17.43% 17.43% +6.2%
NPM % 9.14% 9.80% 9.80% +7.2%
Other Income ₹33 Cr ₹30 Cr ₹30 Cr -8.2%
Depreciation ₹43 Cr ₹46 Cr ₹46 Cr +6.8%
Interest ₹30 Cr ₹27 Cr ₹27 Cr -12.6%
EBIT ₹107 Cr ₹139 Cr ₹139 Cr +30.0%
PBT ₹109 Cr ₹138 Cr ₹138 Cr +26.7%
Tax ₹26 Cr ₹26 Cr ₹26 Cr -1.1%
Net Profit ₹83 Cr ₹104 Cr ₹104 Cr +24.5%
EPS ₹5.41 ₹6.55 ₹6.55 +21.1%
Material Cost ₹552 Cr ₹326 Cr ₹326 Cr -40.8%
Employee Cost ₹144 Cr ₹118 Cr ₹118 Cr -18.0%
Extraordinary Items — ₹-3 Cr ₹-3 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 13141416 +14.3%
Reserves 393438828923 +11.5%
Borrowings 268305280260 -7.1%
Other Liabilities 207191221225 +1.8%
Total Liabilities 8829481,3431,424 +6.0%
Fixed Assets 584699729791 +8.5%
CWIP 95334032 -20.0%
Investments 12151515 +0.0%
Other Assets 192200559585 +4.7%
Total Assets 8829481,3431,424 +6.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 129108139129 -7.2%
Cash from Investing Activity -153-90-388-96 +75.3%
Cash from Financing Activity 30-26277-41 -114.8%
Net Cash Flow 7-828-8 -128.6%
Free Cash Flow -5364625 -45.7%
CFO/OP 140%95%102%81% -20.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 43363738 +2.7%
Cash Conversion Cycle 43363738 +2.7%
Working Capital Days -45-29-29-19 +34.5%
ROCE % 11%14%15%15% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 66.53%66.53%58.38%58.39%58.39% +0.0%
FIIs 0.24%0.37%12.47%12.19%12.46% +2.2%
DIIs 4.76%4.27%2.91%2.89%1.91% -33.9%
Government 7.02%7.02%6.16%6.16%6.16% +0.0%
Public 21.45%21.81%20.07%20.37%21.08% +3.5%
No. of Shareholders 31,61433,55931,60232,04444,260 +38.1%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Artemis Medicare Services Limited's revenue in Q4 FY26?
Artemis Medicare Services Limited reported revenue of ₹274 crore for the quarter ended March 2026 (Q4 FY26), up 16.6% from ₹235 crore in the same quarter last year, and up 2.5% sequentially over the December 2025 quarter.
What was Artemis Medicare Services Limited's net profit in Q4 FY26?
Net profit rose 29.3% year-on-year to ₹30 crore, from ₹23 crore. Earnings per share (EPS) came in at ₹1.87.
What is ARTEMISMED's market capitalisation and P/E ratio?
At the current price of ₹306.35, ARTEMISMED has a market capitalisation of ₹4,799 crore and a trailing P/E of about 46.2.
Who owns Artemis Medicare Services Limited? (shareholding pattern)
As of Sep 2026, promoters held 58.39%, foreign institutional investors (FIIs) 12.46%, domestic institutional investors (DIIs) 1.91%, the government 6.16%, public shareholders 21.08% of Artemis Medicare Services Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI